Danzig C, Khanani A, Loewenstein A
Immunotherapy. 2024; 16(12):779-790.
PMID: 39073397
PMC: 11457614.
DOI: 10.1080/1750743X.2024.2368342.
Zheng L, Duan Y, He P, Wu M, Wei S, Du X
Cell Mol Biol Lett. 2024; 29(1):81.
PMID: 38816685
PMC: 11140885.
DOI: 10.1186/s11658-024-00602-9.
Boeckel H, Karsten C, Gopel W, Herting E, Rupp J, Hartel C
Int J Mol Sci. 2023; 24(12).
PMID: 37373467
PMC: 10299388.
DOI: 10.3390/ijms241210321.
Lazzaro A, De Girolamo G, Filippi V, Innocenti G, Santinelli L, Ceccarelli G
Int J Mol Sci. 2022; 23(2).
PMID: 35054993
PMC: 8776148.
DOI: 10.3390/ijms23020803.
Wu Q, Yin C, Li Y, Cai J, Yang H, Huang Y
Front Pharmacol. 2021; 12:769190.
PMID: 34938184
PMC: 8687625.
DOI: 10.3389/fphar.2021.769190.
Simultaneous Measurement of Changes in Neutrophil Granulocyte Membrane Potential, Intracellular pH, and Cell Size by Multiparametric Flow Cytometry.
Stratmann A, Wohlgemuth L, Erber M, Bernhard S, Hug S, Fauler M
Biomedicines. 2021; 9(11).
PMID: 34829733
PMC: 8614908.
DOI: 10.3390/biomedicines9111504.
Signaling pathways and intervention therapies in sepsis.
Zhang Y, Ning B
Signal Transduct Target Ther. 2021; 6(1):407.
PMID: 34824200
PMC: 8613465.
DOI: 10.1038/s41392-021-00816-9.
Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).
Bauer M, Weyland A, Marx G, Bloos F, Weber S, Weiler N
Crit Care Explor. 2021; 3(11):e0577.
PMID: 34806021
PMC: 8601347.
DOI: 10.1097/CCE.0000000000000577.
Clinicopathological features and prognostic significance of C5aR in human solid tumors: a Meta-analysis.
Wang Z, Yu W, Qiang Y, Ma F, Ding P, Wang Y
BMC Cancer. 2021; 21(1):1136.
PMID: 34688269
PMC: 8540875.
DOI: 10.1186/s12885-021-08883-5.
A Bittersweet Response to Infection in Diabetes; Targeting Neutrophils to Modify Inflammation and Improve Host Immunity.
Dowey R, Iqbal A, Heller S, Sabroe I, Prince L
Front Immunol. 2021; 12:678771.
PMID: 34149714
PMC: 8209466.
DOI: 10.3389/fimmu.2021.678771.
Complement C5a-triggered differentiated HL-60 stimulates migration of THP-1 monocytic leukocytes via secretion of CCL2.
Dewan S, Osaka M, Deushi M, Yoshida M
FEBS Open Bio. 2021; 11(5):1374-1381.
PMID: 33715310
PMC: 8091577.
DOI: 10.1002/2211-5463.13144.
Ion and Water Transport in Neutrophil Granulocytes and Its Impairment during Sepsis.
Messerer D, Schmidt H, Frick M, Huber-Lang M
Int J Mol Sci. 2021; 22(4).
PMID: 33567720
PMC: 7914618.
DOI: 10.3390/ijms22041699.
Complement C5a Induces Pro-inflammatory Microvesicle Shedding in Severely Injured Patients.
Karasu E, Demmelmaier J, Kellermann S, Holzmann K, Kohl J, Schmidt C
Front Immunol. 2020; 11:1789.
PMID: 32983087
PMC: 7492592.
DOI: 10.3389/fimmu.2020.01789.
C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling.
Wood A, Vassallo A, Ruchaud-Sparagano M, Scott J, Zinnato C, Gonzalez-Tejedo C
JCI Insight. 2020; 5(15).
PMID: 32634128
PMC: 7455072.
DOI: 10.1172/jci.insight.137029.
Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis.
Cao C, Yu M, Chai Y
Cell Death Dis. 2019; 10(10):782.
PMID: 31611560
PMC: 6791888.
DOI: 10.1038/s41419-019-2015-1.
Toll-like receptor 2 confers partial neuroprotection during prion disease.
Carroll J, Race B, Williams K, Chesebro B
PLoS One. 2019; 13(12):e0208559.
PMID: 30596651
PMC: 6312208.
DOI: 10.1371/journal.pone.0208559.
Mechanistic Understanding of Single-Cell Behavior is Essential for Transformative Advances in Biomedicine.
Francis E, Heinrich V
Yale J Biol Med. 2018; 91(3):279-289.
PMID: 30258315
PMC: 6153630.
Complement C5a Alters the Membrane Potential of Neutrophils during Hemorrhagic Shock.
Messerer D, Denk S, Fohr K, Halbgebauer R, Braun C, Hones F
Mediators Inflamm. 2018; 2018:2052356.
PMID: 30002598
PMC: 5996468.
DOI: 10.1155/2018/2052356.
Extension of chemotactic pseudopods by nonadherent human neutrophils does not require or cause calcium bursts.
Francis E, Heinrich V
Sci Signal. 2018; 11(521).
PMID: 29535263
PMC: 7053518.
DOI: 10.1126/scisignal.aal4289.
Glycogen synthase kinase‑3β inhibitor reduces LPS‑induced acute lung injury in mice.
Ding Q, Liu G, Zeng Y, Zhu J, Liu Z, Jiang J
Mol Med Rep. 2017; 16(5):6715-6721.
PMID: 28901469
PMC: 5865788.
DOI: 10.3892/mmr.2017.7469.